CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BCD274ExpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPembrolizumab,NivolumabCarbognin et al., 2015
BSMOMutationPredictiveSupportsResistanceBasal Cell CarcinomaVismodegibAtwood et al., 2015
DSMOMutationPredictiveSupportsSensitivity/ResponseBasal Cell CarcinomaPSI,Arsenic TrioxideAtwood et al., 2015
BPTCH1MutationPredictiveSupportsSensitivity/ResponseMedulloblastomaSonidegibKool et al., 2014
BSTK11EXON 1-2 MUTATIONPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaPécuchet et al., 2017
BDNAJB1::PRKACAFusionDiagnosticSupportsPositiveFibrolamellar CarcinomaCornella et al., 2015
ACDKN2Ap16 ExpressionPrognosticSupportsBetter OutcomeOropharynx CancerAng et al., 2010
BCDKN2Ap16 ExpressionPredictiveDoes Not SupportResistanceOropharynx CancerCetuximabRosenthal et al., 2016
CEML4::ALKFusion AND ALK L1152RPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSasaki et al., 2011
CEML4::ALKFusion AND ALK G1269APredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibDoebele et al., 2012
DERBB4MutationPredictiveSupportsSensitivity/ResponseMelanomaLapatinibPrickett et al., 2009
BEGFRVIIIPredictiveSupportsSensitivity/ResponseGlioblastomaEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorMellinghoff et al., 2005
BPTENExpressionPredictiveSupportsSensitivity/ResponseGlioblastomaEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorMellinghoff et al., 2005
DNRG1ExpressionPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaLapatinibWilson et al., 2011
DNRG1ExpressionPredictiveSupportsResistanceColorectal CancerCetuximabYonesaka et al., 2011
DEGFRG724SPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabCho et al., 2014
DEGFRG719SPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximabCho et al., 2014
CMAPK1E322KPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaErlotinibVan Allen et al., 2015
DMAPK1AmplificationPredictiveSupportsResistanceLung Non-small Cell CarcinomaWZ4002Ercan et al., 2012
BERCC1ExpressionPredictiveDoes Not SupportSensitivity/ResponseBladder CarcinomaCisplatinKlatte et al., 2015
BNRG1ExpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPatritumabMendell et al., 2015
BBRAFV600EPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,PanitumumabRowland et al., 2015
BPDCD4EXPRESSIONPredictiveSupportsSensitivity/ResponseLung CancerPaclitaxelXu et al., 2015
CEML4::ALKFusion AND ALK L1198F AND ALK C1156YPredictiveSupportsResistanceLung Non-small Cell CarcinomaLorlatinibShaw et al., 2016
CEML4::ALKFusion AND ALK L1198F AND ALK C1156YPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibShaw et al., 2016
DTP53MutationPredictiveSupportsSensitivity/ResponseBreast CancerDoxorubicinJackson et al., 2012
BAURKAOverexpressionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCisplatinXu et al., 2014
DRAC1P29SPredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibWatson et al., 2014
DATMUnderexpressionPredictiveSupportsSensitivity/ResponseGastric AdenocarcinomaOlaparibKubota et al., 2014
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibSequist et al., 2013
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibSequist et al., 2013
BHSPA5EXPRESSIONPredictiveSupportsSensitivity/ResponseColorectal CancerFluorouracilThornton et al., 2013
BPIK3CAMutationPredictiveSupportsResistanceColorectal CancerAnti-EGFR Monoclonal AntibodyWu et al., 2013
BFOXP3EXPRESSIONPredictiveSupportsSensitivity/ResponseBreast CancerEpirubicinLadoire et al., 2012
DJAK1OVEREXPRESSIONPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaEnzastaurinShimokawa et al., 2012
DKRASMutationPredictiveSupportsSensitivity/ResponseCancerTrametinibJing et al., 2012
DBRAFMutationPredictiveSupportsSensitivity/ResponseCancerTrametinibJing et al., 2012
BEGFRAmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorDahabreh et al., 2011
BCDX2EXPRESSIONPrognosticSupportsBetter OutcomeColorectal CancerDalerba et al., 2016
BSTAT3SH2 DOMAIN MUTATIONDiagnosticSupportsPositiveT-cell Large Granular Lymphocyte LeukemiaKoskela et al., 2012
BEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibJänne et al., 2015
BERBB2SERUM LEVELSPredictiveSupportsSensitivity/ResponseBreast CancerLapatinibLee et al., 2016
DIDH1R132HPredictiveSupportsSensitivity/ResponseOligodendrogliomaAGI-5198Rohle et al., 2013
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibWu et al., 2014
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibWu et al., 2014
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaAfatinibYang et al., 2015
BMYD88L265PPredictiveSupportsSensitivity/ResponseLymphoplasmacytic LymphomaIbrutinibTreon et al., 2015
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerB-Raf/VEGFR-2 Inhibitor RAF265,SelumetinibLamba et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerTrametinib,AfatinibSun et al., 2014
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DocetaxelJänne et al., 2013
Page 9 of 96
PreviousNext